Treatment of hypercholesterolaemia with oral lecithin

Aust N Z J Med. 1977 Jun;7(3):262-6. doi: 10.1111/j.1445-5994.1977.tb03683.x.


An open clinical trial was performed to evaluate the plasma cholesterol-lowering potential of oral lecithin in large doses (20--30 g/day), with or without supplementary clofibrate. Three healthy subjects and seven patients with hypercholesterolaemia were studied over periods ranging from eight weeks to 11 months. In one-third of healthy subjects and in 3/7 patients, lecithin therapy led to a significant fall in plasma cholesterol concentration (10--18% fall). Combination of lecithin and clofibrate in two of the patients led to still lower plasma cholesterol levels (21 and 22% fall). Most of the change in plasma cholesterol concentration, when it occurred, was due to a reduction in beta lipoproteins. Evidence is presented that oral lecithin may reduce plasma cholesterol levels by acting as a source of linoleic acid.

MeSH terms

  • Adult
  • Cholesterol / blood
  • Clofibrate / administration & dosage
  • Clofibrate / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Phosphatidylcholines / administration & dosage*
  • Phosphatidylcholines / therapeutic use
  • Triglycerides / blood


  • Lipoproteins, LDL
  • Phosphatidylcholines
  • Triglycerides
  • Cholesterol
  • Clofibrate